Eli Lilly and Company is investing $700 million to build a state-of-the-art facility in the Boston Seaport, as part of plans to advance its RNA-based research and development activities. The new Lilly Institute for Genetic Medicine was launched on February 22 and built on Lilly’s acquisition of Prevail Therapeutics, the New York-based gene therapy developer, in 2020. At the new facility, researchers and scientists from both New York and Boston will be working together to build on their expertise in RNA- and DNA-based technologies to create treatments for diseases with large unmet needs. Their focus would be to prevent or treat illnesses that traditional medicines cannot. Eli Lilly’s genetic medicine research efforts already account for over 20% of its immunology, diabetes and central nervous system portfolio. The firm expects manpower at its new Boston site to grow from 120 to over 250 in the next five years to include more chemists, research biologists, data scientists and other genetic medicine experts. Its New York facility is also expected to expand to as many as 200 scientists in-house.
For further information see Biospace (https://www.biospace.com/article/eli-lilly-launches-state-of-the-art-boston-facility-to-advance-rna-dna-based-treatments/?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsmi=204701505&_hsenc=p2ANqtz-_NVLJ0WsLBjUYBc2uJssp3toZToPWdZyIm94xQWiLHY7mhsfDbaUz5wl7cNV8X5dLFTXhsernNapNSV_LW1ooYjQuRDA&utm_content=204701505&utm_source=hs_email)
